Form 4: Tevogen Bio Holdings Director Receives 240,000 Restricted Stock Units

Director Susan M Podlogar of Tevogen Bio Holdings Inc. was granted 240,000 restricted stock units (RSUs) on December 23, 2024, which will vest over four years.

Summary

• Susan M Podlogar, a director at Tevogen Bio Holdings Inc., received 240,000 restricted stock units (RSUs) on December 23, 2024.
• These RSUs were granted under the company's 2024 Omnibus Incentive Plan.
• The RSUs will vest in four equal annual installments, starting on January 1, 2025.
• Vesting is contingent upon Ms. Podlogar remaining in service with the company on the vesting dates.
• Each RSU represents the right to receive one share of Tevogen Bio Holdings Inc.'s common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally viewed positively as it aligns the interests of management with shareholders. There are no negative implications or surprises.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The vesting of the RSUs is contingent on the director's continued service with the company, which introduces a risk of forfeiture if the director leaves before full vesting.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

The granting of stock-based compensation is a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock-based compensation, such as RSUs, is a standard practice in the biotech industry, often used to incentivize directors and executives.
• The four-year vesting schedule is also a common practice, designed to encourage long-term commitment and performance.
• Comparable companies in the biotech sector often use similar equity-based compensation plans to attract and retain talent.

Stakeholder Impact

• The RSU grant may have a minor dilutive effect on existing shareholders, but it is intended to incentivize a key member of the board.
• The vesting schedule encourages long-term commitment from the director, which is beneficial for the company's stakeholders.

Key Dates

Keywords

restricted stock units, RSUs, stock grant, director compensation, Tevogen Bio Holdings, equity compensation, incentive plan